Raptor Pharmaceutical Completes DR Cysteamine Phase 2b Clinical Trial in Cystinosis

Monday, November 23, 2009 General News
Email Print This Page Comment bookmark
Font : A-A+

Goal of Trial Achieved Demonstrating Potentially Less Frequent Administration Using Lower Daily Dose

For more information, please contact:

Karl Cahill, Investor Relations

(858) 531-6100

kcahill@raptorpharma.com

The Ruth Group

Sara Ephraim Pellegrino (investors) / Janine McCargo (media)

(646) 536-7002 / (646) 536-7033

spellegrino@theruthgroup.com / jmccargo@theruthgroup.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook